



Rep. Laura Faver Dias

Filed: 4/8/2025

10400HB2346ham001

LRB104 06540 BDA 24827 a

1 AMENDMENT TO HOUSE BILL 2346

2 AMENDMENT NO. _____. Amend House Bill 2346 by replacing
3 everything after the enacting clause with the following:

4 "Section 5. The Illinois Drug Reuse Opportunity Program
5 Act is amended by changing Sections 5, 45, and 55 and by adding
6 Section 70 as follows:

7 (410 ILCS 715/5)

8 Sec. 5. Definitions. In this Act:

9 "Controlled substance" means a drug, substance, or
10 immediate precursor in Schedules I through V of 21 CFR 1308.

11 "Department" means the Illinois Department of Public
12 Health.

13 "Dispense" has the same meaning as defined in Section 3 of
14 the Pharmacy Practice Act.

15 "Donor" means any person, including an individual member
16 of the public, or any entity legally authorized to possess

1 medicine, including, but not limited to, a wholesaler or
2 distributor, third party logistic provider, pharmacy,
3 dispenser, clinic, surgical or health center, detention and
4 rehabilitation center, jail, prison laboratory, medical or
5 pharmacy school, prescriber or other health care professional,
6 long-term care facility, or healthcare facility. "Donor"
7 includes government agencies and entities that are federally
8 authorized to possess medicine, including, but not limited to,
9 drug manufacturers, repackagers, relabelers, outsourcing
10 facilities, health care facilities operated by the U.S.
11 Department of Veterans Affairs, and prisons.

12 "Drug" means a prescription drug, over-the-counter drug,
13 or supplies needed to administer a prescription or
14 over-the-counter drug.

15 "Eligible patient" means an individual:

16 (1) with a prescription for the drug, if a
17 prescription is required to dispense the drug, or who
18 reports symptoms treated by the drug if the drug is
19 over-the-counter; and

20 (2) who is registered with the drug's manufacturer in
21 accordance with federal Food and Drug Administration
22 requirements, if the registration is required to dispense
23 the drug.

24 "Manufacturer" has the same meaning as defined in Section
25 15 of the Wholesale Drug Distribution Licensing Act.

26 "Pharmacist" means an individual licensed to engage in the

1 practice of pharmacy under the Pharmacy Practice Act or
2 licensed to engage in the practice of pharmacy in another
3 state.

4 "Practitioner" means a person licensed in this State to
5 dispense or administer drugs or who is licensed in another
6 state as a person authorized to dispense or administer drugs.

7 "Prescription drug" means any prescribed drug that may be
8 legally dispensed by a pharmacy. "Prescription drug" does not
9 include a drug for the treatment of cancer that can only be
10 dispensed to a patient registered with the drug manufacturer
11 in accordance with the federal Food and Drug Administration's
12 requirements.

13 "Priority patient" means an eligible patient who is an
14 Illinois resident and who is indigent, uninsured,
15 underinsured, or enrolled in a public health benefits program.

16 "Recipient" means any person or entity legally authorized
17 to possess medicine with a license or permit in the state in
18 which the person or entity is located, including, but not
19 limited to, a wholesaler or distributor, reverse distributor,
20 repackager, hospital, pharmacy, or clinic.

21 "Returns processor" has the same meaning as defined in
22 paragraph (18) of 21 U.S.C. 360eee. "Returns processor"
23 includes, but is not limited to, a reverse distributor.

24 "Unopened tamper-evident packaging" has the same meaning
25 as defined in the United States Pharmacopeia (USP) General
26 Chapter 659, Packaging and Storage Requirements, including,

1 but not limited to, unopened unit-dose, multiple-dose,
2 immediate, secondary, and tertiary packaging.

3 (Source: P.A. 102-389, eff. 1-1-22.)

4 (410 ILCS 715/45)

5 Sec. 45. Recordkeeping requirements. When performing any
6 action associated with a program under this Act or otherwise
7 processing a donated drug for tax, manufacturer, or other
8 credit, a recipient shall be considered to be acting as a
9 returns processor and shall comply with all recordkeeping
10 requirements for nonsalable ~~nonsaleable~~ returns under federal
11 law. Records maintained under this Act may be accessed by the
12 Department upon request.

13 (Source: P.A. 102-389, eff. 1-1-22.)

14 (410 ILCS 715/55)

15 Sec. 55. Retention of records. All records required under
16 this Act shall be retained in physical or electronic format
17 and on or off the recipient's premises for a period of 6 years.
18 Donors or recipients may contract with one another or a third
19 party to create or maintain records on each other's behalf. An
20 identifier, such as a serial number or bar code, may be used in
21 place of any or all information required by a record or label
22 pursuant to this Act if it allows for such information to be
23 readily retrievable. Upon request by a State or federal
24 regulatory agency, the identifier used for requested records

1 shall be replaced with the original information. An identifier
2 shall not be used on patient labels when dispensing or
3 administering a drug. Records maintained under this Act may be
4 accessed by the Department upon request.

5 (Source: P.A. 102-389, eff. 1-1-22.)

6 (410 ILCS 715/70 new)

7 Sec. 70. Program support provided by the Department.

8 (a) The Department shall:

9 (1) develop, maintain, and publish on its website
10 information regarding the names and locations of
11 pharmacies participating in the Illinois Drug Reuse
12 Opportunity Program;

13 (2) educate pharmacies in the State about the Illinois
14 Drug Reuse Opportunity Program and how to participate in
15 it voluntarily;

16 (3) develop and publish educational materials to allow
17 program participants and the Department to inform the
18 general public about the purposes and benefits of the
19 program; and

20 (4) collect information from participants and publish
21 the information in an annual report to the General
22 Assembly by December 31 of each calendar year, beginning
23 December 31, 2026.

24 (b) Pharmacy participants are required to notify the
25 Department of their participation in any program under this

- 1 Act and report any data required in a format established by the
- 2 Department.".